Chemoradiation
Chemoradiation
& NSCLC Review Articles - Recent MEDLINE Abstracts (PubMed)
Combined
Modality Therapy: New Insights, Old Roadblocks (Medscape)
Summary, by Corey Langer, MD, of findings presented at the 9th World
Conference on Lung Cancer (September 2000). Discusses the implications
of several studies that address the use of combined modality therapy in
patients with locally advanced NSCLC. Notes that combined modality therapy,
particularly concurrent chemoradiation, has become the standard of practice
in fit patients with unresectable NSCLC. Aimed at physicians. Registration
required for free access to Medscape. [9/00]
Innovative
Treatment Strategies in Locally Advanced and/or Unresectable NSCLC
(Moffitt Cancer Center)
by Benjamin Movsas, MD
7, no.1 Cancer Control (January/February 2000): 25-34
Reviews trials investigating innovative treatment strategies for patients
with locally advanced and/or unresectable NSCLC, including altered radiation
fractionation schema, conformal 3-dimensional radiotherapy, and combined
chemoradiotherapy regimens.
Chemotherapy & Surgery
Neoadjuvant Chemotherapy
Neoadjuvant
Chemotherapy for NSCLC - Recent MEDLINE Abstracts (PubMed)
Preoperative
Chemotherapy for Lung Cancer Does Not Increase Surgical Morbidity
(Annals of Thoracic Surgery)
Abstract of a study reported in the April 2001 issue of the Annals
of Thoracic Surgery that found preoperative chemotherapy for NSCLC
did not significantly affect overall morbidity or mortality. Concludes
that the potential for enhanced survival in resectable NSCLC justifies
continued study of preoperative chemotherapy. [4/01]
Adjuvant Chemotherapy
Adjuvant
Chemotherapy for NSCLC - Recent MEDLINE Abstracts (PubMed)
Post-Surgery
Chemotherapy Improves Survival in Early Lung Cancer (National
Cancer Institute)
Discusses the results of two large randomized studies that demonstrated
in early-stage NSCLC, treatment after surgery with chemotherapy improves
overall survival compared to surgery alone. The findings help resolve
a controversy over the value of post-surgical chemotherapy for early lung
cancer and are likely to change the standard of care. [5/04]
Radiation & Surgery
Radiation
& Surgery for NSCLC - Recent MEDLINE Articles (PubMed)
Adding
Chemotherapy to Radiation After Surgery Adds No Benefit in Lung Cancer
(NCI's cancer.gov)
Reports on a study published in the 10/26/00 issue of the New
England Journal of Medicine that found adding chemotherapy to radiation
therapy does not prolong survival in operable NSCLC. The large, randomized
study compared the chemotherapy (cisplatin and etoposide) and radiation
combination to radiation alone. Patients receiving the combined treatment
had a median survival of 38 months compared to 39 months among those receiving
radiation alone. Overall survival and recurrence rates were also similar
in the two groups. [10/00]
Chemotherapy, Radiation & Surgery
Three-Pronged
Approach an Added Treatment Option for NSCLC Spread to Surrounding Lymph
Nodes (National Cancer Institute)
Reports on a study presented at the 2003 ASCO annual meeting that
found patients with NSCLC that has spread to surrounding lymph nodes who
were treated with a three-pronged approach using chemotherapy, radiation
and surgery lived longer than patients treated with just chemotherapy
and radiation. Notes that it remains unclear whether three-pronged treatment
extends patients' overall survival compared to the two-pronged approach.
[6/03]
Multimodality
Treatment for NSCLC - Recent MEDLINE Articles (PubMed)
|
